**Agenda Scientific Session – October 3, 2020**

11:00 am ET (10 min) **Welcome** - Samm Masterson (introduce the planning committee) and Dr. Araya Puwanant (welcome everyone)

11:10 am ET (5 min) **Introduction Dr. Kaminski** (argenx Team to make introductions)

11:15 am ET (30 min) **Open with Dr. Henry Kaminski** - Keynote Speaker

11:45 am ET (10 min) **Q & A** – Moderated by Araya Puwanant, MD

11:55 am ET (20 min) **Poster Break**

12:15 pm ET (5 min) **Introduction MG Diagnostics** (Alexion Team to make introductions)

**MG Diagnostics**

12:20 pm ET (20 min) **Presentations on Cell-Based Assays**

- Jeffrey Guptill, MD
  
  VALIDATION OF A LIVE CLUSTERED CELL BASED ACETYLCHOLINE RECEPTOR ASSAY IN A COHORT OF DOUBLE SERONEGATIVE DEFINITE MYASTHENIA GRAVIS PATIENTS

- Hans Frykman, MD, PhD
  
  LIVE CELL-BASED ASSAY FOR ANTIBODIES TO CLUSTERED ACETYLCHOLINE RECEPTOR IN MYASTHENIA GRAVIS, CROSS VALIDATION, INTER-ASSAY STABILITY AND UTILITY IN A PAEDIATRIC COHORT SUSPECTED FOR MG

12:40 pm ET (5 min) **Q & A** - Moderated by Araya Puwanant, MD

12:45 pm ET (15 min)

- Miriam Fichtner, MD
  
  AFFINITY MATURATION IS REQUIRED FOR PATHOGENIC MONOVALENT IGG4 AUTOANTIBODY DEVELOPMENT IN AUTOIMMUNE MYASTHENIA GRAVIS

1:00 pm ET (5 min) **Q & A** - Moderated by Araya Puwanant, MD

(5-minute transition)

1:10 pm ET (15 min) **Data Blitz #1: Focused on Diagnostics**

- Ki Hoon Kim, MD
  
  ANTI-TITIN ANTIBODIES ARE FREQUENTLY OBSERVED IN PATIENTS WITH MYASTHENIA GRAVIS WHO EXPERIENCED THE RECURRENCE OF THYMOMA

- Pritikanta Paul, MBBS
  
  REFLEX ALGORITHM FOR IMPROVING ACCURACY OF MYASTHENIA GRAVIS AUTOANTIBODY TESTING
• Faraz S. Hussain, PhD
  PROTEOMIC PROFILING MAY REVEAL NOVEL BIOMARKERS FOR MYASTHENIA GRAVIS
  1:25 pm ET (5 min) Q & A - Moderated by Araya Puwanant, MD

1:30 pm ET (20 min) Exhibit Hall Break

1:50 pm ET (5 min) Introduction – MG, COVID and MG Registries (UCB Team to make introductions)

MG, COVID and MG Registries
1:55 pm ET (30 min) Presentations on COVID-related Topics
• Amanda Guidon, MD
  FEASIBILITY AND ACCEPTABILITY OF REMOTE MONITORING OF PATIENTS WITH MYASTHENIA GRAVIS USING DIGITAL TECHNOLOGY
• Srikanth Muppidi, MD
  COVID-19 ASSOCIATED RISKS AND EFFECTS IN MYASTHENIA GRAVIS (CARE-MG): AN INTERNATIONAL PHYSICIAN-REPORTED REGISTRY
  2:25 pm ET (5 min) Q & A - Moderated by Srikanth Muppidi, MD
  (5-minute transition)

2:35 pm ET (15 min) Data Blitz #2: Focused on COVID and Registries
• Jeffrey Guptill, MD
  KNOWLEDGE AND PERCEPTIONS OF THE COVID-19 PANDEMIC AMONG PATIENTS WITH MYASTHENIA GRAVIS
• Megan Barra, MD
  IMPACT OF A MYASTHENIA GRAVIS DRUG-DISEASE INTERACTION CLINICAL DECISION SUPPORT TOOL ON PROVIDER PRESCRIBING
• Donald Sanders, MD
  THE DUKE MYASTHENIA GRAVIS CLINIC REGISTRY: DESCRIPTION AND DEMOGRAPHICS
  2:50 pm ET (5 min) Q & A - Moderated by Srikanth Muppidi, MD

2:55 pm ET (20 min) Poster Break

3:15 pm ET (5 min) Introduction MG Clinical Trials (Momenta Team to make introductions)

MG Clinical Trials
3:20 pm ET (30 min) Presentations on Clinical Trials
• Jeffrey Guptill, MD
  A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PK, AND PD OF NIPOCALIMAB (M281) IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
• James Howard, MD
  TREATMENT OF PATIENTS WITH MYASTHENIA GRAVIS WITH EFGARTIGIMOD: RESULTS OF THE PHASE 3 ADAPT STUDY
  3:50 pm ET (5 min) Q & A – Moderated by Shruti M. Raja, MD
  (5-minute transition)
4:00 pm ET (15 min) Data Blitz #3: Trials/New Strategies

- Richard J. Nowak, MD, MS
  THE MYASTHENIA GRAVIS INEBILIZUMAB TRIAL (MINT): DESIGN OF RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY OF AN ANTI-CD19 MONOCLONAL ANTIBODY IN GENERALIZED MYASTHENIA GRAVIS

- Suraj Muley, MD, FAAN
  TWO-YEAR POST-MARKETING SAFETY EXPERIENCE OF ECULIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN THE UNITED STATES

- Sangwook Oh, PhD
  MUSCLE-SPECIFIC TYROSINE KINASE CHIMERIC AUTOANTIBODY RECEPTOR T CELLS (MUSK-CAART) AS A PRECISION CELLULAR IMMUNOTHERAPY FOR ANTIGEN-SPECIFIC B CELL DEPLETION IN MUSK MYASTHENIA GRAVIS (MG)

4:15 pm ET (5 min) Q & A - Moderated by Shruti M. Raja, MD

4:15 pm ET (5 min) Closing Remarks – Thank you(s) – Samm Masterson

4:20 pm ET (30 min) Poster Break and Exhibit Break

**Agenda subject to change**